InvestorsHub Logo
Followers 8
Posts 288
Boards Moderated 0
Alias Born 11/12/2018

Re: None

Friday, 03/01/2019 5:22:03 AM

Friday, March 01, 2019 5:22:03 AM

Post# of 424639
Not picking up on any negative vibes after listening to the Leerink conference call. The lady interviewing JT was well versed and respectful and the pair of them laughed together twice towards the end of the interview.

JT answered the Q's very well, particularly the placebo question.

He said that the sNDA was almost ready for submission and that they were "planning for an ADCOM". I fully expect one too because of the sheer size of the patient population involved.

That will be the mother of all biotech binary events if it happens. A positive vote at that and shareholders are officially off to the promised land. I also fully expect an AZN rep to be on the panel in the same mould as Dr. Hyatt (he had ties with AZN), pushing hard with the placebo inertness angle and trying to influence the other panel members to vote negatively so that approval is stalled until AZN announce their outcomes data. This indication is big business and I fully expect AZN to continue to play dirty.

Who's gonna have the balls to hold all their shares going into another ADCOM of that magnitude?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News